Barclays Initiates Coverage of Sutro Biopharma (STRO) with Overweight Recommendation
29/5 02:03
Fintel reports that on May 28, 2026, Barclays initiated coverage of Sutro Biopharma (NasdaqGM:STRO) with a Overweight recommendation. Analyst Price Forecast Suggests 14.40% Upside...